INSILICO

3696
35.5605.98% ( -2.260 )
Delay Closed: Nov 16, 16:08:11

Overview

INSILICO (3696)

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platfo...

Open
37.820
High
37.820
Low
34.300
Prev. Close
37.820
Volume
12.14M
Turnover
426.50M
Avg Price
35.142
Bid/Ask Ratio
-94.67%
Amplitude
9.31%
52wk High
80.900
Volume Ratio
0.69
Turnover Ratio
2.07%
52wk Low
29.980
HK Mkt Cap
20.88B
Market CapHKD
20.88B
P/ETTM
Loss
P/EDynamic
37.46
P/EStatic
--
EPSTTM
-3.97
EPSDynamic
0.949
EPSStatic
--
BVPS
7.31
P/B
4.87
HK Shares
587.11M
Dividend YieldTTM
--
DividendTTM
--
Shares
587.11M
Min lot size
500
Currency
HKD

INSILICO Analyst Rating

View more

Forecast & Rating

Nov 12, 2026
Price forecast
HK$77.89119.03%
Forecast & RatingStrong buy
11analysts
  • Strong buy72.73%
  • Buy27.27%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Insilico Medicine opened at its session high of 37.82 HKD and slid 5.9% to close at 35.58 HKD, touching 34.34 HKD at 14:09 BJ before the closing auction lifted it back to 35.56 HKD on 421 million HKD of turnover and a 2.04% turnover rate. The pullback coincided with broader weakness in AI drug discovery names and debate over how much of the sector's deal value rests on milestone payments not yet triggered. Fundamentals ran the other way: Q2 2026 revenue reached 416.9 million HKD, up 286.8% year on year, with net profit of 139.4 million HKD at a 33.4% margin and EPS of 0.2353 HKD, up 124%. A subsidiary signed an AI drug discovery partnership with Luoxin Pharmaceuticals, ISM6331 showed a 40% response rate at 130 mg in a Phase 1 mesothelioma trial, and the company has flagged a buyback of up to 500 million HKD. Even so, the stock trades below MA20 of 37.63 HKD and MA60 of 46.23 HKD, down 5.32% year to date and roughly 56% below its 80.90 HKD 52-week high, at 4.87x book with a negative P/E. Late buying did suggest some support near the lows.

  2. Nov, 13

    Shares fell 3.42% to HK$37.82, opening at HK$39.00, sliding to a HK$37.00 afternoon low before recovering into the close, as the AI drug-discovery sector weakened and investors booked profits after the prior session's 6% bounce; turnover reached HK$339 million. That tape sits oddly against Q2 2026 revenue of HK$416.9 million (+286.82% yoy), net profit of HK$139.4 million (+284.78%), EPS of HK$0.2353 (+123.98%) and a 40% response rate at 130 mg for ISM6331 in a Phase 1 mesothelioma trial, while the company has flagged a buyback of up to HK$500 million and most brokers still rate it buy. Yet the stock is up only 0.64% year to date and sits 53.25% below its 19 February high of HK$80.90, hugging the 20-day MA at HK$37.798 but still far under the 60-day MA at HK$46.372, with a HK$22.2 billion market cap at 5.18x book. Though Chainfir Capital warns AI drug-licensing headlines may mask reliance on uncertain milestone payments.

  3. Nov, 10

    Insilico Medicine closed up 2.47% at HK$38.94, with sustained buybacks the clearest driver: 199,000 shares repurchased for HK$7.562 million on November 9 and 400,000 shares for HK$15.0059 million on November 6, on top of a previously announced buyback plan of up to HK$500 million. The session traced a spike-and-fade pattern, opening at HK$39.50, printing the intraday high of HK$39.98 at 09:31, sliding to HK$38.78 at 11:19 and then trading in a narrow HK$38.78-39.46 band through the afternoon to settle at HK$38.94, with an all-day average of HK$39.255 on HK$248.7 million turnover and a thin 1.08% turnover rate. Fundamentals cut against the price: Q2 2026 revenue of HK$416.9 million grew 286.82% year on year and net profit of HK$139.4 million rose 284.78%, a 33.43% net margin and EPS of HK$0.2353, yet the stock is up only 3.62% year to date, holding above its MA20 of HK$38.123 but 51.87% below the 52-week high of HK$80.90 and under its MA60 of HK$46.531. Though AstraZeneca has publicly said it is too early to claim AI can cure cancer, tempering the sector narrative while biotech volatility widens.

  4. Nov, 9

    Insilico Medicine staged an intraday pullback today, rising to HK$39.72 in the morning session before sliding to HK$37.70 in the afternoon and closing at HK$38.00, a roughly 5.3% intraday range, as early support from a buyback plan of up to HK$500 million and positive ISM6331 data at ESMO gave way to a biotech retreat, with GenScript Bio down 12% and the sector index off 2%. The operating picture contrasts with the share price: Q2 revenue was HK$416.86 million, up 286.82% year on year, net profit HK$139.36 million, up 284.78%, and net margin 33.43%, yet the price remains below its 20-day MA of HK$38.53 and 60-day MA of HK$46.62, about 53% below the 52-week high of HK$80.90 and roughly 27% above the 52-week low of HK$29.98. The company also repurchased 400,000 shares for HK$15.0059 million last Friday, while total turnover reached HK$353.32 million on 9.12 million shares and the turnover rate was 1.55%; though AI-drug-discovery validation concerns and sector volatility kept the close under pressure.

  5. Nov, 6

    Insilico Medicine fell 4.88% to HK$37.46 today, as a biotech-sector pullback and fading AI-drug enthusiasm drove the session, producing an intraday spike-and-fade: the stock dipped to HK$36.34 at 09:31, rose to HK$38.72 at 10:40, and closed at HK$37.46 on 12.90 million shares worth HK$481.7 million. GenScript Bio fell 12% and the biotech index lost 2%, while AstraZeneca questioned claims that AI could cure diseases within a decade. The operating print cuts the other way: Q2 revenue rose 286.82% year on year to HK$416.86 million, net profit rose 284.78% to HK$139.36 million, net margin was 33.43%, and EPS rose 123.98% to HK$0.2353; the company also plans a buyback of up to HK$500 million and a RMB300 million fund. At HK$37.46, the stock sits 53.7% below its 52-week high of HK$80.90, 24.95% above its 52-week low of HK$29.98, down 0.32% YTD, below its MA20 of HK$39.09 and MA60 of HK$46.77, with a 2.2% turnover rate and HK$21.99 billion market cap, though the buyback and earnings improvement offer some support.

News

Bullish vs. Bearish — Last 3 Months

9.9k followers · 1 opinions
▲Bullish100%
  • L
    Lele

    $INSILICO(03696.HK)

    Grid Setup: Prioritize Grids 1-2. We recommend activating 2 grids above and below to avoid exceeding purchasing power. With 500 shares per grid, the max buy requirement is HKD 37,900. Given a purchasing power of HKD 32,858, Grid 1 is actionable. Step size is ~HKD 0.24.

    Stop-loss at HKD 29.50: This sits just below the 52-week low (29.98). A break below signals a fundamental shift, invalidating the grid strategy.

    Watch for the Aug 31 MSCI effective date: Passive inflows could push the price into the dense MA zone (44-45), an ideal trigger to sell on Grid 1.

    Expected Profit per Grid: Based on a 5.8% step, each full buy-sell cycle yields ~HKD 1,200/lot. Triggering 1-2 times monthly generates HKD 1,200-2,400, sufficient to cover financing interest.

  • P
    Profit

    Zai Lab's commercialization and licensing model in China has seen multiple products included in the national reimbursement drug list (NRDL), with high visibility for revenue growth in 2026.

    JD Health, a leader in internet healthcare, continues to see growth in monthly active users and online penetration of prescription drugs. Improved consumer sentiment post-ceasefire is beneficial for platform transaction volume.

    Insilico Medicine is a globally representative company in AI-driven drug discovery, with pipeline progress being a short-term catalyst. Its latest funding round valued the company at over $600 million, and it is currently in a window of valuation re-rating as it transitions from an AI tool provider to a clinical-stage pipeline company.

  • M
    momoM

    $INSILICO(03696.HK) first all in this, then top up $FOREST CABIN(02657.HK)